

NUVASIVE INC  
Form 8-K  
December 22, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 16, 2005

**NUVASIVE, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**000-50744**  
(Commission File  
Number)

**33-0768598**  
(I.R.S. Employer Identification  
Number)

**4545 Towne Centre Court, San Diego, California 92121**

(Address of principal executive offices, with zip code)

**(858) 909-1800**

(Registrant's telephone number, including area code)

n/a

## Edgar Filing: NUVASIVE INC - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry Into A Material Definitive Agreement**

On December 16, 2005, NuVasive, Inc. (the Company) entered into Master Technology and Services Agreement Amendment #1 with Medidata Solutions, Inc., which amends the Master Technology and Services Agreement originally executed by the parties on September 2, 2005 (together, the Agreement). Under the Agreement, Medidata granted the Company licenses to use its electronic clinical data management technology and agreed to provide support services during clinical studies of certain of the Company's investigational medical devices.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
10.1*	Master Technology and Services Agreement dated September 2, 2005, and Master Technology and Services Agreement Amendment #1 dated December 16, 2005, each between the Company and Medidata Solutions, Inc.

\* Certain confidential portions of this exhibit were omitted by means of redacting a portion of the text. This exhibit has been filed separately with the Secretary of the Commission without the redactions pursuant to our Application Requesting Confidential Treatment under the Securities Exchange Act of 1934.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NUVASIVE, INC.**

Date: December 22, 2005

By: /s/ **ALEXIS V. LUKIANOV**  
Alexis V. Lukianov

Chairman and Chief Executive Officer

-3-

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
10.1*	Master Technology and Services Agreement dated September 2, 2005, and Master Technology and Services Agreement Amendment #1 dated December 16, 2005, each between the Company and Medidata Solutions, Inc.

\* Certain confidential portions of this exhibit were omitted by means of redacting a portion of the text. This exhibit has been filed separately with the Secretary of the Commission without the redactions pursuant to our Application Requesting Confidential Treatment under the Securities Exchange Act of 1934.